# Hepatic Reirradiation for Patients with Recurrent Hepatocellular Carcinoma
## 3 Results
The result confirmed that Child-Pugh classification as a survival-predicting model for the patients with liver cirrhosis. For tumor volumes of less than 100 cm\({}^{3}\), it seemed that smaller tumors had marginal benefit on OS (\(p\) = 0.059) and IF-PFS (\(p\) = 0.075) (Table 2). However, the presence of PVTT in the main portal vein was shown to have no impact on both the OS and LC after RT (\(p\) = 0.099 and 0.141, respectively) (Supplementary Table S4). Figure 2: (**A**) Overall survival for the patients with complete remission (CR) and the patients with partial remission (PR); (**B**) infield progression-free survival for the patients with CR and the patients with PR. \begin{table}
\begin{tabular}{c c c c c c c} \hline \hline \multirow{2}{*}{**Prognostic Factor**} & \multicolumn{2}{c}{**No. of Patient**} & \multicolumn{2}{c}{**Infield Progression-Free Survival**} & \multicolumn{2}{c}{**Overall Survival (OS)**} \\  & \multicolumn{2}{c}{**Patient**} & \multicolumn{2}{c}{**(IF-PFS)**} & \multicolumn{2}{c}{**Univariate**} & \multicolumn{2}{c}{**Multivariate**} \\ \hline  & & **Univariate** & **Multivariate** & **Univariate** & **Multivariate** \\ \hline  & \(\mathbf{n}\) **(\%)** & \(\mathbf{p}\) **Value** & \begin{tabular}{c} **HR 1** \\ **(95\% CI 2)** \\ \end{tabular} & \(\mathbf{p}\) **Value** & \begin{tabular}{c} **\(\mathbf{p}\) **Value** \\ **(95\% CI 2)** \\ \end{tabular} & \(\mathbf{p}\) **Value** & \begin{tabular}{c} **HR** \\ **(95\% CI)** \\ \end{tabular} & \(\mathbf{p}\) **Value** \\ \hline Local control & & & & \(<\)0.001 & \begin{tabular}{c} 0.170 \\ (0.035–0.829) \\ \end{tabular} & 0.028 \\ Regression subgroup & 27 (84.4\%) & & & & \\ Stable subgroup & 5 (15.6\%) & & & & \\ Regression subgroup & & 0.940 & & 0.860 & \\ Complete remission & 8 (25\%) & & & & \\ Partial remission & 19 (59.4\%) & & & & \\ BCLC stage & & 0.326 & & 0.114 & \\ Stage A & 5 (15.6\%) & & & & \\ Stage B & 15 (46.9\%) & & & & \\ Stage C & 12 (37.5\%) & & & & \\ Use of systemic therapy & & 0.591 & & 0.513 & \\ Use & 8 (25.0\%) & & & & \\ Nonuse & 24 (75.0\%) & & & & \\ Outfield recurrence and/or & & 0.072 & \begin{tabular}{c} 3.320 \\ (0.933–11.812) \\ \end{tabular} & 0.064 & 0.706 & \\ distant metastasis & & & & & \\ Nil & 6 (18.8\%) & & & & \\ Presence & 26 (81.3\%) & & & & \\ Child–Pugh score before & & \begin{tabular}{c} 0.228 \\ (0.085–0.612) \\ \end{tabular} & 0.003 & 0.005 & \begin{tabular}{c} 0.325 \\ (0.129–0.820) \\ \end{tabular} & 0.017 \\ re-RT & & 22 (68.8\%) & & & & \\ Child–Pugh score 5 & 10 (31.3\%) & & & & \\ Tumor volume & & 0.075 & \
\begin{tabular}{c} 0.488 \\ (0.172–1.383) \\ \end{tabular} & 0.177 & 0.059 &
\begin{tabular}{c} 0.782 \\ (0.299–2.047) \\ \end{tabular} & 0.617 \\ Tumor volume \(\geq\) 100 (cm\({}^{3}\)) & 17 (53.1\%) & & & & \\ \hline \hline \end{tabular}
\end{table} 
Table 2: Univariate and multivariate analysis of infield progression-free survival and overall survival. Figure 3: Overall survival for Child–Pugh score 5 subgroup and Child–Pugh score 6 and 7 subgroup. Systemic therapy, including chemotherapy and target therapy, might be added after reirradiation (Supplementary Table S5); however, the use of systemic therapy or not was shown to have no benefit on the OS (\(p\) = 0.513) and IF-PFS (\(p\) = 0.591) (Figure 4A,B). It also had no benefit on 6-month, 12-month and 24-month IF-PFS with \(p\) = 0.232, 0.281, and 0.475, respectively (Supplementary Table S6). This suggested local RT had a more important effect than systemic therapy in LC. OF and DM-PFS were used to calibrate the effect of systemic therapy. The association between the use of systemic therapy with OF and/or DM-PFS was statistically insignificant (\(p\) = 0.423)  
Univariate analysis suggested that the use of systemic therapy and the presence of main PVTT had no relation to survival. Despite the tumor stage, only LC and Child-Pugh score were independently associated with the OS under multivariate analysis.